Related Experiment Video

Updated: May 15, 2026

Isolation of Intermediate Filament Proteins from Multiple Mouse Tissues to Study Aging-associated Post-translational Modifications
09:29

Isolation of Intermediate Filament Proteins from Multiple Mouse Tissues to Study Aging-associated Post-translational Modifications

Published on: May 18, 2017

mTOR is a key modulator of ageing and age-related disease

Simon C Johnson1, Peter S Rabinovitch, Matt Kaeberlein

  • 1Department of Pathology, University of Washington, Seattle, Washington 98195, USA.

Nature
|January 18, 2013
PubMed

Insights

Pharmacological interventions targeting the mechanistic target of rapamycin (mTOR) pathway show promise for slowing aging. While current drugs have side effects, future therapies could reduce age-related diseases.

Area of Science:

  • Gerontology and pharmacology
  • Cellular signaling pathways
  • Drug development for aging

Background:

  • Aging is a complex biological process with increasing research into interventions.
  • The mechanistic target of rapamycin (mTOR) pathway is a key regulator of cellular responses to nutrients.
  • mTOR pathway inhibition has demonstrated lifespan extension and protection against age-related diseases in model organisms.

Purpose of the Study:

  • To review the potential of pharmacological interventions targeting the mTOR pathway for slowing aging.
  • To discuss the current status and future prospects of mTOR inhibitors in human healthspan.

Main Methods:

  • Literature review of studies on mTOR pathway and aging.
  • Analysis of existing clinical data on mTOR inhibitors.
  • Discussion of potential therapeutic applications and challenges.

Main Results:

  • Inhibition of the mTOR pathway extends lifespan and improves healthspan in various model organisms.
  • Several mTOR inhibitors are already approved for clinical use, with others in development.
  • Adverse effects currently limit the use of mTOR inhibitors in healthy individuals.

Conclusions:

  • Pharmacological targeting of the mTOR pathway represents a promising strategy for slowing human aging.
  • Further research and development are needed to overcome side effects and optimize therapeutic use.
  • mTOR inhibitors may become crucial in managing age-related pathologies and promoting longevity.

More Related Videos

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitochondria01:37

Mitochondria

Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...